- Home
- NFBK vs SRDX Comparison
NFBK vs SRDX Comparison
Compare NFBK & SRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- SRDX
- Stock Information
- Founded
- NFBK 1887
- SRDX 1979
- Country
- NFBK United States
- SRDX United States
- Employees
- NFBK N/A
- SRDX N/A
- Industry
- NFBK Major Banks
- SRDX Medical/Dental Instruments
- Sector
- NFBK Finance
- SRDX Health Care
- Exchange
- NFBK Nasdaq
- SRDX Nasdaq
- Market Cap
- NFBK 406.5M
- SRDX 415.4M
- IPO Year
- NFBK 2007
- SRDX 1998
- Fundamental
- Price
- NFBK $12.22
- SRDX $29.99
- Analyst Decision
- NFBK Buy
- SRDX Buy
- Analyst Count
- NFBK 2
- SRDX 2
- Target Price
- NFBK $13.00
- SRDX $43.00
- AVG Volume (30 Days)
- NFBK 210.0K
- SRDX 87.0K
- Earning Date
- NFBK 07-23-2025
- SRDX 07-30-2025
- Dividend Yield
- NFBK 4.26%
- SRDX N/A
- EPS Growth
- NFBK 1.58
- SRDX N/A
- EPS
- NFBK 0.76
- SRDX N/A
- Revenue
- NFBK $128,407,000.00
- SRDX $121,575,000.00
- Revenue This Year
- NFBK $12.68
- SRDX N/A
- Revenue Next Year
- NFBK $15.15
- SRDX $3.70
- P/E Ratio
- NFBK $16.06
- SRDX N/A
- Revenue Growth
- NFBK N/A
- SRDX N/A
- 52 Week Low
- NFBK $8.92
- SRDX $26.00
- 52 Week High
- NFBK $14.39
- SRDX $42.44
- Technical
- Relative Strength Index (RSI)
- NFBK 59.51
- SRDX 57.37
- Support Level
- NFBK $11.39
- SRDX $28.90
- Resistance Level
- NFBK $12.17
- SRDX $30.49
- Average True Range (ATR)
- NFBK 0.39
- SRDX 0.78
- MACD
- NFBK 0.02
- SRDX 0.03
- Stochastic Oscillator
- NFBK 85.83
- SRDX 73.32
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About SRDX Surmodics Inc.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.